ABMC Reports Third Quarter 2016 Results

- November 14th, 2016

American Bio Medica Corporation today announced financial results for the three and nine months ended September 30, 2016.

American Bio Medica Corporation (OTCPK:ABMC) today announced financial results for the three and nine months ended September 30, 2016.
Chief Executive Officer Melissa A. Waterhouse stated, “We are continuing
to take steps to halt the sales declines we have been experiencing for
some time now but, admittedly organic growth in our industry is
challenging. Additional product and service offerings and a
reorganization and refocus of our sales and marketing department are
underway. At the same time, we are reviewing other potential
relationships that could enable ABMC to further broaden its product
offerings and branch out into other markets.”
Waterhouse continued, “Gross profits were negatively impacted in the
third quarter of 2016. Our gross profit was 43.1% of net sales in the
third quarter of 2016 compared to 48.2% in the third quarter of 2015.
This decline is a direct result of less strip production in the third
quarter 2016 when expenses to manufacture remained flat. We do not
expect further significant declines in gross profits. And finally, from
an operational perspective, we will continue to be fiscally conservative
and keep expenses in line with revenues.”
Financial Highlights

  • Net sales in the third quarter of 2016 were $1,417,000 compared to
    $1,590,000 in the third quarter of 2016, a decrease of 10.9%. Net
    sales in the nine months ended September 30, 2016 were $4,392,000
    compared to net sales of $4,785,000 in the nine months ended September
    30, 2015, a decrease of 8.2%.
  • Operating loss was $60,000 in the third quarter of 2016 compared to an
    operating income of $61,000 in the third quarter of 2015. Operating
    loss was $136,000 in the nine months ended September 30, 2016,
    compared to an operating loss of $80,000 in the nine months ended
    September 30, 2015.
  • Net loss was $88,000 in the third quarter 2016, compared to a net loss
    of $2,000 in the third quarter of 2015. Net loss was $130,000 in both
    the nine months ended September 30, 2016 and September 30, 2015.

For more information on ABMC or its drug testing products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation manufactures and markets accurate,
cost-effective immunoassay test kits, primarily point of collection
tests for drugs of abuse. The Company and its worldwide distribution
network target the workplace, government, corrections, clinical and
educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS®
InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or
absence of drugs of abuse in urine, while OralStat® tests for the
presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid
Reader® is a compact, portable device that, when connected to any
computer, interprets the results of an ABMC drug screen, and sends the
results to a data management system, enabling the test administrator to
easily manage their drug testing program.
This release may contain forward-looking statements. These
forward-looking statements involve risks and uncertainties that could
cause actual results to differ, and such differences could be material.
Such risks and uncertainties include, but are not limited to, risks and
uncertainties related to the following: continued acceptance of our
products, increased levels of competition in our industry, acceptance of
new products, product development, compliance with regulatory
requirements, including but not limited to our ability to obtain
marketing clearance on our product for our intended markets,
intellectual property rights, our dependence on key personnel, third
party sales and suppliers, trading in our common shares may be subject
to “penny stock” rules, our history of recurring net losses and our
ability to continue as a going concern. There can be no assurance that
the Company will be successful in addressing such risks and
uncertainties and the Company assumes no duty to update any
forward-looking statements based upon actual results. Investors are
strongly encouraged to review the section entitled “Risk Factors” in the
Company’s annual report on Form 10-K for the year ended December 31,
2015, quarterly reports on Form 10-Q, and other periodic reports on file
with the Securities and Exchange Commission for a discussion of risks
and uncertainties that could affect operating results and the market
price of the Company’s common shares.

AMERICAN BIO MEDICA CORPORATION
Condensed Statements of Operations
(unaudited)
For the three For the three For the nine For the nine
months ended months ended months ended months ended

September 30,

September 30,

September 30,

September 30,

2016

2015

2016

2015

Net sales $ 1,417,000 $ 1,590,000 $ 4,392,000 $ 4,785,000
Cost of goods sold 806,000 823,000 2,441,000 2,543,000
Gross profit 611,000 767,000 1,951,000 2,242,000
Operating expenses:
Research and development 28,000 45,000 136,000 125,000
Selling and marketing 275,000 291,000 827,000 899,000
General and administrative 368,000 370,000 1,124,000 1,298,000
Total operating expenses 671,000 706,000 2,087,000 2,322,000
Operating income / (loss) (60,000 ) 61,000 (136,000 ) (80,000 )
Other income / (expense) (27,000 ) (63,000 ) 8,000 (50,000 )
Net loss before tax (87,000 ) (2,000 ) (128,000 ) (130,000 )
Income tax expense (1,000 ) 0 (2,000 ) 0
Net loss $ (88,000 ) $ (2,000 ) $ (130,000 ) $ (130,000 )
Basic & diluted loss per common share $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.01 )
Weighted average shares outstanding – basic and diluted

27,284,308

26,032,930

27,056,216

25,557,021

American Bio Medica Corporation
Condensed Balance Sheets
September 30, December 31,

2016

2015

(unaudited)

ASSETS
Current Assets
Cash and cash equivalents $ 221,000 $ 158,000
Accounts receivable, net of allowance for doubtful accounts of
$50,000 at September 30, 2016 and December 31, 2015

721,000

672,000

Inventory, net of allowance of $495,000 at September 30, 2016 and
$432,000 at December 31, 2015

1,556,000

1,746,000

Prepaid expenses and other current assets 61,000 40,000
Total current assets 2,559,000 2,616,000
Property, plant and equipment, net 844,000 910,000
Patents, net 70,000 67,000
Other assets 21,000 14,000
Deferred finance costs – line of credit, net 55,000 79,000
Total assets $ 3,549,000 $ 3,686,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable 305,000 373,000
Accrued expenses and other current liabilities 225,000 212,000
Wages payable 281,000 292,000
Line of credit 736,000 777,000
Current portion of long-term debt 75,000 75,000
Total current liabilities 1,622,000 1,729,000
Other liabilities 19,000 38,000
Related party note 0 124,000
Long-term debt, net of current portion and deferred finance costs 730,000 834,000
Total liabilities 2,371,000 2,725,000
COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity:
Common stock 285,000 260,000
Additional paid-in capital 20,979,000 20,656,000
Accumulated deficit (20,086,000 ) (19,955,000 )
Total stockholders’ equity 1,178,000 961,000
Total liabilities and stockholders’ equity $ 3,549,000 $ 3,686,000

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply